Genprex
GNPX
6 hedge funds and large institutions have $1.6M invested in Genprex in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
37% less capital invested
Capital invested by funds: $2.52M → $1.6M (-$923K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$42.2K |
| 2 |
Renaissance Technologies
New York
|
+$42.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$84.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$14K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 5 |
TA
TCG Advisors
Austin,
Texas
|
-$2K |
GNPX Hedge Fund Activity: Q3 2019 in Review
6 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q3 2019, worth a combined $1.6M — down 37% from $2.52M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new GNPX positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $42.2K. The largest seller was Sabby Management, cutting an estimated $84.5K.
- 6 institutional investors held Genprex (GNPX) as of Q3 2019, up from 5 in Q2 2019.
- Funds reported $1.6M of Genprex stock for Q3 2019, down 37% quarter-over-quarter.
- 2 funds opened new Genprex positions in Q3 2019 and 1 closed out, a net change of +1 holder.
- The largest Genprex buyer in Q3 2019 was Goldman Sachs, an estimated $42.2K added.
- The largest Genprex seller in Q3 2019 was Sabby Management, an estimated $84.5K sold.
Based on aggregated 13F filings for Q3 2019.